The Associations of Advanced Glycation End Products and Its Soluble Receptor with Pancreatic Cancer Risk: A Case-Control Study within the Prospective EPIC Cohort.
(2012) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21(4). p.619-628- Abstract
- BACKGROUND: Advanced glycation end products (AGE) and their receptors (RAGE) have been implicated in cancer development through their proinflammatory capabilities. However, prospective data on their association with cancer of specific sites, including pancreatic cancer, are limited.METHODS: Prediagnostic blood levels of the AGE product Nε-(carboxymethyl)lysine (CML) and the endogenous secreted receptor for AGE (esRAGE) were measured using ELISA in 454 patients with exocrine pancreatic cancer and individually matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic cancer risk was estimated by calculating ORs with corresponding 95% confidence intervals (CI).RESULTS: Elevated CML levels... (More)
- BACKGROUND: Advanced glycation end products (AGE) and their receptors (RAGE) have been implicated in cancer development through their proinflammatory capabilities. However, prospective data on their association with cancer of specific sites, including pancreatic cancer, are limited.METHODS: Prediagnostic blood levels of the AGE product Nε-(carboxymethyl)lysine (CML) and the endogenous secreted receptor for AGE (esRAGE) were measured using ELISA in 454 patients with exocrine pancreatic cancer and individually matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic cancer risk was estimated by calculating ORs with corresponding 95% confidence intervals (CI).RESULTS: Elevated CML levels tended to be associated with a reduction in pancreatic cancer risk [OR = 0.57 (95% CI, 0.32-1.01) comparing highest with lowest quintile), whereas no association was observed for esRAGE (OR = 0.98; 95% CI, 0.62-1.54). Adjustments for body mass index and smoking attenuated the inverse associations of CML with pancreatic cancer risk (OR = 0.78; 95% CI, 0.41-1.49). There was an inverse association between esRAGE and risk of pancreatic cancer for cases that were diagnosed within the first 2 years of follow-up [OR = 0.46 (95% CI, 0.22-0.96) for a doubling in concentration], whereas there was no association among those with a longer follow-up (OR = 1.11; 95% CI, 0.88-1.39; P(interaction) = 0.002).Conclusions and Impact: Our results do not provide evidence for an association of higher CML or lower esRAGE levels with risk of pancreatic cancer. The role of AGE/RAGE in pancreatic cancer would benefit from further investigations. Cancer Epidemiol Biomarkers Prev; ©2012 AACR. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2367343
- author
- Grote, Verena A
; Nieters, Alexandra
; Kaaks, Rudolf
; Tjønneland, Anne
; Roswall, Nina
; Overvad, Kim
; Nielsen, Michael R Skjelbo
; Clavel-Chapelon, Françoise
; Boutron-Ruault, Marie Christine
; Racine, Antoine
; Teucher, Birgit
; Lukanova, Annekatrin
; Boeing, Heiner
; Drogan, Dagmar
; Trichopoulou, Antonia
; Trichopoulos, Dimitrios
; Lagiou, Pagona
; Palli, Domenico
; Sieri, Sabina
; Tumino, Rosario
; Vineis, Paolo
; Mattiello, Amalia
; Suárez, Marcial Vicente Argüelles
; Duell, Eric J
; Sánchez, María-José
; Dorronsoro, Miren
; Castaño, José María Huerta
; Barricarte, Aurelio
; Jeurnink, Suzanne M
; Peeters, Petra H M
; Sund, Malin
; Ye, Weimin
; Regnér, Sara
LU
; Lindkvist, Björn
; Khaw, Kay-Tee
; Wareham, Nick
; Allen, Naomi E
; Crowe, Francesca L
; Fedirko, Veronika
; Jenab, Mazda
; Romaguera, Dora
; Siddiq, Afshan
; Bueno-de-Mesquita, H Bas
and Rohrmann, Sabine
(Less) - organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- volume
- 21
- issue
- 4
- pages
- 619 - 628
- publisher
- American Association for Cancer Research
- external identifiers
-
- wos:000302220600007
- pmid:22301828
- scopus:84859388699
- pmid:22301828
- ISSN
- 1538-7755
- DOI
- 10.1158/1055-9965.EPI-11-1139
- language
- English
- LU publication?
- yes
- id
- d7d5a9fd-2205-4400-afe5-fbcf72962f76 (old id 2367343)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22301828?dopt=Abstract
- date added to LUP
- 2016-04-01 14:49:44
- date last changed
- 2022-04-22 05:24:57
@article{d7d5a9fd-2205-4400-afe5-fbcf72962f76,
abstract = {{BACKGROUND: Advanced glycation end products (AGE) and their receptors (RAGE) have been implicated in cancer development through their proinflammatory capabilities. However, prospective data on their association with cancer of specific sites, including pancreatic cancer, are limited.METHODS: Prediagnostic blood levels of the AGE product Nε-(carboxymethyl)lysine (CML) and the endogenous secreted receptor for AGE (esRAGE) were measured using ELISA in 454 patients with exocrine pancreatic cancer and individually matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic cancer risk was estimated by calculating ORs with corresponding 95% confidence intervals (CI).RESULTS: Elevated CML levels tended to be associated with a reduction in pancreatic cancer risk [OR = 0.57 (95% CI, 0.32-1.01) comparing highest with lowest quintile), whereas no association was observed for esRAGE (OR = 0.98; 95% CI, 0.62-1.54). Adjustments for body mass index and smoking attenuated the inverse associations of CML with pancreatic cancer risk (OR = 0.78; 95% CI, 0.41-1.49). There was an inverse association between esRAGE and risk of pancreatic cancer for cases that were diagnosed within the first 2 years of follow-up [OR = 0.46 (95% CI, 0.22-0.96) for a doubling in concentration], whereas there was no association among those with a longer follow-up (OR = 1.11; 95% CI, 0.88-1.39; P(interaction) = 0.002).Conclusions and Impact: Our results do not provide evidence for an association of higher CML or lower esRAGE levels with risk of pancreatic cancer. The role of AGE/RAGE in pancreatic cancer would benefit from further investigations. Cancer Epidemiol Biomarkers Prev; ©2012 AACR.}},
author = {{Grote, Verena A and Nieters, Alexandra and Kaaks, Rudolf and Tjønneland, Anne and Roswall, Nina and Overvad, Kim and Nielsen, Michael R Skjelbo and Clavel-Chapelon, Françoise and Boutron-Ruault, Marie Christine and Racine, Antoine and Teucher, Birgit and Lukanova, Annekatrin and Boeing, Heiner and Drogan, Dagmar and Trichopoulou, Antonia and Trichopoulos, Dimitrios and Lagiou, Pagona and Palli, Domenico and Sieri, Sabina and Tumino, Rosario and Vineis, Paolo and Mattiello, Amalia and Suárez, Marcial Vicente Argüelles and Duell, Eric J and Sánchez, María-José and Dorronsoro, Miren and Castaño, José María Huerta and Barricarte, Aurelio and Jeurnink, Suzanne M and Peeters, Petra H M and Sund, Malin and Ye, Weimin and Regnér, Sara and Lindkvist, Björn and Khaw, Kay-Tee and Wareham, Nick and Allen, Naomi E and Crowe, Francesca L and Fedirko, Veronika and Jenab, Mazda and Romaguera, Dora and Siddiq, Afshan and Bueno-de-Mesquita, H Bas and Rohrmann, Sabine}},
issn = {{1538-7755}},
language = {{eng}},
number = {{4}},
pages = {{619--628}},
publisher = {{American Association for Cancer Research}},
series = {{Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}},
title = {{The Associations of Advanced Glycation End Products and Its Soluble Receptor with Pancreatic Cancer Risk: A Case-Control Study within the Prospective EPIC Cohort.}},
url = {{http://dx.doi.org/10.1158/1055-9965.EPI-11-1139}},
doi = {{10.1158/1055-9965.EPI-11-1139}},
volume = {{21}},
year = {{2012}},
}